Healthcare provider profile · identity verified

Wenhui Liu, MD

Internal Medicine · SAN DIEGO, CA · NPI 1689733321

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	527	174
Lisinopril	Lisinopril	267	87
Losartan Potassium	Losartan Potassium	244	81
Amlodipine Besylate	Amlodipine Besylate	241	87
Metformin Hcl Er	Metformin Hcl	206	69
Levothyroxine Sodium	Levothyroxine Sodium	193	55
Omeprazole	Omeprazole	153	64
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	134	42
Atenolol	Atenolol	117	34
Metformin Hcl	Metformin Hcl	106	29
Gabapentin	Gabapentin	103	47
Simvastatin	Simvastatin	100	33
Alendronate Sodium	Alendronate Sodium	96	33
Trazodone Hcl	Trazodone Hcl	82	26
Metoprolol Tartrate	Metoprolol Tartrate	78	23
Glipizide	Glipizide	68	24
Potassium Chloride	Potassium Chloride	67	21
Hydrochlorothiazide	Hydrochlorothiazide	60	19
Jardiance	Empagliflozin	53	16
Pravastatin Sodium	Pravastatin Sodium	48	14
Rosuvastatin Calcium	Rosuvastatin Calcium	43	17
Pradaxa	Dabigatran Etexilate Mesylate	42	14
Meloxicam	Meloxicam	37	15
Albuterol Sulfate Hfa	Albuterol Sulfate	36	21
Terazosin Hcl	Terazosin Hcl	36	12
Allopurinol	Allopurinol	34	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	32	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	31	16
Tamsulosin Hcl	Tamsulosin Hcl	29	11
Alprazolam	Alprazolam	28	suppressed
Sertraline Hcl	Sertraline Hcl	28	13
Triamcinolone Acetonide	Triamcinolone Acetonide	28	17
Ondansetron Hcl	Ondansetron Hcl	26	suppressed
Estradiol	Estradiol	25	12
Furosemide	Furosemide	25	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Ondansetron Odt	Ondansetron	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Finasteride	Finasteride	19	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	18	18
Humulin N	Insulin Nph Human Isophane	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Clobetasol Propionate	Clobetasol Propionate	17	suppressed
Eliquis	Apixaban	17	suppressed
Humulin R	Insulin Regular, Human	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	16	16
Donepezil Hcl	Donepezil Hcl	15	suppressed
Fluocinonide	Fluocinonide	15	11
Ibuprofen	Ibuprofen	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Temazepam	Temazepam	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Fluticasone Propionate	Fluticasone Propionate	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Ozempic	Semaglutide	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Alvesco	Ciclesonide	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Nystatin	Nystatin	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Prednisone	Prednisone	12	12
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error